Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients

Next Previous
X
Search
Trial Profile

APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Osimertinib (Primary)
  • Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms APPLE

    • Most Recent Events

    • 06 Apr 2024 This trial has been completed in Poland according to European Clinical Trials Database record.
    • 10 Mar 2024 According to an European Clinical Trials Database record, this trial has been completed in Slovenia.
    • 28 Feb 2023 Results(n=103 ; of Arms B and C) assessing the feasibility of longitudinal plasma EGFR T790M monitoring for the best sequencing strategy of gefitinib and osimertinib published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top